Acclarent, Inc. Granted Key Patent Covering Balloon Sinuplasty(TM) Technologies

MENLO PARK, Calif., May 4 /PRNewswire/ -- Acclarent, Inc., the pioneer of
Balloon Sinuplasty(TM) technologies for use in the treatment of chronic
sinusitis, announced today that the U.S. Patent and Trademark Office awarded
U.S. Patent Number 7,500,971, entitled "Devices, Systems and Methods for
Treating Disorders of the Ear, Nose and Throat," to the company. This patent
and Acclarent's earlier 7,462,175 patent are directed to methods for treating
a paranasal sinus ostium, such as the maxillary sinus ostium, either through
the nostril or other routes. The patented methods include advancing a balloon
through a guide and using the balloon to dilate a paranasal sinus ostium. "In
addition to securing protection for this early innovation, we believe this key
patent underscores Acclarent's strength in intellectual property and deepens
the cornerstone of our patent portfolio for Balloon Sinuplasty(TM)," states
Acclarent CEO, Bill Facteau.

With this latest patent, Acclarent now owns or has exclusive rights to nine
issued U.S. patents and over 120 pending U.S. and foreign patent applications.

"Acclarent's innovative Balloon Sinuplasty(TM) technology has been used by
physicians throughout the world to improve the quality of life for thousands
of patients suffering from chronic rhinosinusitis," said Facteau. "Acclarent
is committed to continuing its leadership in innovation. This patent protects
an important portion of Acclarent's technology assets and further
differentiates Acclarent as a leader in the ENT community. The validation by
the USPTO of our invention is a significant step in continuing to provide
physicians and patients with access to safe and effective minimally invasive
technology."

ABOUT ACCLARENT, INC.
Acclarent is a medical technology company dedicated to the development of
innovative products providing new technologies to further meet the needs of
ENT patients.

Acclarent's initial focus is on achieving the goals of sinus surgery with
novel, endoscopic, catheter-based tools - Balloon Sinuplasty(TM) devices.
Through the Balloon Sinuplasty(TM) technology and our Relieva(R) product
portfolio we offer ENT patients alternatives to conventional endoscopic
surgical approaches. Through our core technologies and commitment to
innovation, Acclarent will continue to advance novel devices in all areas of
ENT. Acclarent markets and sells its products worldwide and has been used by
thousands of physicians globally.

SOURCE Acclarent, Inc.

Investor Relations, George Harter, Chief Financial Officer of Acclarent, Inc.,
+1-650-687-5859